Earnings
Merck, Johnson & Johnson, AstraZeneca and Roche are among the big pharma manufacturers that will face substantial exclusivity losses in the US this year.
As the Danish vaccine maker plots further M&A activity.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Geopolitical events overshadowed Bayer’s financial results announcement, as was also the case for its peers. But Bayer’s history of acquisition and slow portfolio rejuvenation compound the clouds over its investment proposition.
The Swiss company predicted Nemluvio could generate peak sales of $4bn in in prurigo nodularis and atopic dermatitis.
Garijo’s exit comes at a time when Merck gets set to navigate some key headwinds, but without its outgoing chief and her experience in portfolio‑streamlining and targeted acquisitions.
Newer launches in its pharmaceuticals division such as Nubeqa and Kerendia will be core to Bayer’s 2026 growth strategy.
The new indication for ocular myasthenia gravis would target about 7,000 patients and provide another growth opportunity for the blockbuster FcRn inhibitor.
The drug’s launch for hidradenitis suppurativa has been particularly impressive.
The controversial Doug Ingram will depart for personal reasons, following the diagnosis of two family members with myotonic dystrophy.
Amid a wider domestic market downturn, Beijing Health Guard’s three Phase III trials for two of its HPV vaccine candidates were suspended in January and February due to overdue payments to sites.
Cytokinetics, BridgeBio, Ionis and Apellis updated investors on the commercial trajectories of new drug launhces, while Alkermes announced CEO Richard Pops will retire.
After announcing the acquisitions of Inozyme and Amicus last year, the rare disease specialist is continuing to scout out pipeline expansion opportunities.
PTC sees the PKU drug approved in July as its near-term growth driver, with geographic expansion expected. It is working with the FDA to refile vatiquinone for Friedreich’s ataxia.
With its first-to-market position in MASH, Madrigal plans to build an enduring franchise to take advantage of growth that it projects will mirror the IBD, RA and psoriasis markets.
A pivotal year lies ahead for its Roche-partnered obesity hopeful petrelintide.
With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.
The company expressed disappointment at the FDA’s decision to reject the mRNA flu vaccine’s submission, during its fourth-quarter earnings call on Feb. 13.
Aurobindo has pushed its projection of an inflection point for biosimilars ahead by a year to FY29 but plans to launch a generic to BMS blockbuster Pomalyst (pomalidomide) in the current quarter. Meanwhile, anti-competitive pricing of penicillin-G by China should now cause less harm
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.